Updates, advisories and surprises

(7:22 PM ET) LOS ANGELES (MarketWatch) -- Elpida Memory Inc.(JP:6665)
ELPDF
Japan's only remaining major DRAM-chip maker, said Tuesday talks to secure capital to ease the company's debt burdens weren't going smoothly, with the revelation raising doubts on Elpida's future. Elpida had been in negotiations with the government and other entities, but said in its last earnings statement that "material uncertainty about its assumed going concern is found." According to Reuters, Elpida is the third largest DRAM supplier in the world, after South Korean rivals Samsung Electronics Co.
SSNLF, -4.49%
and Hynix Semiconductor Inc. Shares of Elpida remained ask-only 20 minutes into Wednesday trading in Tokyo.

MetLife reports $1.1 billion quarterly profit

(4:28 PM ET) SAN FRANCISCO (MarketWatch) -- MetLife Inc.
MET, -1.92%
on Tuesday reported a fiscal fourth-quarter profit of $1.1 billion, or $1.06 a share, on total revenue of $16.4 billion. During the same period a year ago, MetLife earned $51 million, or 5 cents a share, on $13.8 billion in sales. Operating profit for the insurance giant was $1.4 billion, or $1.31 a share. Analysts surveyed by FactSet Research had forecast MetLife to earn $1.24 a share on $16.9 billion in sales.

Peet's Coffee profit down 12%; backs outlook

(4:21 PM ET) SAN FRANCISCO (MarketWatch) -- Peet's Coffee & Tea
PEET
late Tuesday posted a 12% drop in fourth-quarter profit from a year ago, weighed down by steeper costs for unroasted green coffee beans and milk. Profit was $5.6 million, or 42 cents a share, down from $6.4 million, or 48 cents a share, in the same 2010 period. Revenue rose 11% to $101.6 million. The results fell shy of Wall Street's forecast. Analysts had hoped for a profit of 43 cents a share on sales of $103 million. Peet's, based in the San Francisco Bay Area, backed its 2012 financial outlook, however. Shares fell 4% to $65.50 in late trades. The stock has been a high-flier, gaining 62% over the past 12 months and outpacing heady gains made by Starbucks
SBUX, -0.22%

Zynga posts loss; adjusted earnings beat targets

(4:13 PM ET) SAN FRANCISCO (MarketWatch) -- Zynga Inc. posted a net loss for the fourth quarter, though adjusted earnings for the quarter came in ahead of Wall Street's estimates. For the period ended Dec. 31, Zynga
ZNGA, +0.40%
reported a net loss of $435 million, or $1.22 a share, compared to net earnings of $43 million, or 5 cents a share, for the same period the previous year. On a non-GAAP basis, the company said it would have earned $37.2 million, or 5 cents a share, for the recent period. Revenues jumped 59% to $311.2 million. Analysts were expecting earnings of 3 cents a share on revenue of $302 million, according to consensus forecasts from FactSet Research.

Capella Education drops 8% on earnings miss

(11:54 AM ET) CHICAGO (MarketWatch) -- Shares of for-profit school operator Capella Education Co.
CPLA, +0.78%
fell 8% Tuesdsay after the company reported worse-than-expected earnings in the fourth quarter on steadily declining enrollments. Capella said it earned 85 cents a share in the period, shy of the 91-cent estimate of analysts polled by Thomson Reuters.

Hospira shares jump on strong earnings report

(10:36 AM ET) SAN FRANCISCO (MarketWatch) -- Hospira Inc.
HSP, +0.06%
shares rose as much as 9% at the open Tuesday, making it the biggest percentage gainer in the S&P 500 Index. The move followed the release of the specialty pharmaceutical and medication company's latest quarterly results before the opening bell. While one-time charges pushed Hospira to a fourth-quarter loss of $1.30 a share, its adjusted results from ongoing operations produced a profit of 51 cents a share, topping the 45 cents analysts were looking for. The company also topped revenue estimates, up 2.2% at $1.01 billion. Analysts had expected sales of $962 million. Hospira shares were last up 7% at $36.62, extending their advance since Jan. 1 to 20%.

Watson Pharma gains on higher profit target

(10:35 AM ET) SAN FRANCISCO (MarketWatch) -- Watson Pharmaceuticals
WPI, +15.00%
shares rose 4% to $60.09 Tuesday morning, advancing after the generic drug maker raised its 2012 profit outlook. Shares were among the biggest percentage advancers on the S&P 500
SPX, -0.23%
Watson, which began selling the generic version of Pfizer's
PFE, +0.92%
Lipitor cholesterol-lowering drug during the fourth quarter, said it expects to have 2012 revenue of $5.4 billion, and adjusted, non-GAAP earnings of $5.50 to $5.80 a share. That's up from from its old target for a profit between $5.25 and $5.55 a share on $5.3 billion in revenue.

Goodyear Tire shares slide on outlook

(10:17 AM ET) SAN FRANCISCO (MarketWatch) -- Goodyear Tire & Rubber
GT, +1.29%
shares were among the biggest percentage losers on the S&P 500
SPX, -0.23%
Tuesday morning, sliding 6% to $13.11. Goodyear posted its first annual profit in three years but forecast slowing demand for tires worldwide and warned it faces raw material increases of 20% to 25% for the first quarter. Also, Goodyear's adjusted fourth-quarter profit of 3 cents a share lagged the 20-cent profit analysts polled by FactSet had expected. For 2011, Goodyear earned $321 million, reversing a $216 million loss in 2010. Sales for the year rose to $22.7 billion from $18.8 billion.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information. Intraday data
delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc.
All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More
information on NASDAQ traded symbols and their current financial status. Intraday
data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM)
from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is
at least 60-minutes delayed. All quotes are in local exchange time.